![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
SUMMARY
Background: Weight gain is a frequent side-effect of thiazolidinediones, possibly related to fluid retention and stimulation of pre-adipocyte differentiation.
Methods: We report our experience with a low-calorie diet (800cal, sodium content 1500 mmol day−1) combined with behavior modification on eight patients treated with thiazolidinediones (six pioglitazone and two rosiglitazone).
Results: All patients had reported previous weight gain following treatment with thiazolidinediones. All patients lost weight over 12 weeks in the program with their mean ± SD body weight falling from 270 ± 54 lbs (123 ± 25 kg) to 244 ± 61 lbs (111 ± 28 kg) (p < 0.01). The weight loss observed was no different from that observed
in 16 age- and gender-matched patients with type 2 diabetes not treated with thiazolidinediones (from 263 ± 54 lbs (120 ± 25 kg) to 239 ± 52 lbs (109 ± 24 kg); p < 0.01). Glycemic control improved while reducing insulin treatment. Blood pressure control also improved and antihypertensive medications were decreased. The degree and time course of weight loss is no different from that in patients treated with other diabetic therapies and is associated with improved glycemic and blood pressure control.
Conclusions: We conclude that a program of caloric restriction and behavior modification is effective in leading to weight loss in patients treated with thiazolidinediones. This effect is reassuring, since thiazolidinediones stimulate adipogenesis.